Aethlon Medical Reports on Landmark Human Study.

Safety and Viral Capture Documented in Health Compromised Hepatitis-C Patients

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has published a paper entitled: "A Clinical Report on the Safety of the Aethlon Hemopurifier(TM)." The report details the landmark use of the Hemopurifier(TM) in a human infectious disease study conducted at the Apollo Hospital in Delhi, India. The Hemopurifier(TM) is a first-in-class device designed to fill the void in treating drug and vaccine resistant pathogens. The report is available online at: www.aethlonmedical.com/pdfs/ApolloHospitalSafetyStudy.pdf

"The Apollo study advances our mission to establish the industry for medical devices to treat infectious disease," stated Aethlon Chairman & CEO James A. Joyce. "The study also triggers our regulatory endeavors in the United States and sets the stage for us to expand efforts to treat multiple disease targets in India," concluded Joyce.

The report details clinical data collected during a study sponsored by Aethlon Medical to demonstrate the safety of the Hemopurifier(TM) in health-compromised humans. The study also provided an opportunity to observe the capture of Hepatitis-C virus ("HCV") from HCV infected end stage renal disease ("ESRD") study subjects undergoing intermittent dialysis. In tested cartridges, up to 52% of pre-treatment viral load was captured during a single treatment with the Hemopurifier(TM). Twenty-four Hemopurifier cartridges were tested on four study subjects suffering from ESRD and HCV infection. Each cartridge purified the blood of study subjects for up to four hours in six sequential treatments per patient every two to three days. All enrolled patients completed the entire treatment regimen.

About Aethlon Medical

Aethlon Medical is developing the first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets, including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher Frost & Sullivan recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.